References
- Estey Thall E., Pierce F. P, Kantarjian S., Keating H. M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–490
- Sanz M, Lo Coco A., Martin F., Awisati G., Rayon G., Barbui C., Díaz-Mediavilla T., Fioritoni J., Gonzalez G., Liso D. J, Esteve V., Ferrara J., Bolufer F., Bernasconi P., Gonzalez C., Rodeghiero M., Colomer F., Petti D., Ribera C. M, Mandelli M. J. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247–1253
- Fenaux Castaigne P., Chomienne S., Dombret C., Degos H. L. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992; 6: 64–66
- Ding Li W., Nobile P. Y, Grills M. L, Carrera G., Tallman I., Wiernik S. MPH., Gallagher R E. Retinoic acid receptor alpha (RARV)-region mutations in the PML-RARV fusion gene of acute promyelocytic leukemia (APL) patients after relapse from all-trans retinoic acid (ATRA) therapy. Blood 1997; 90(10, suppl 1)415a, (Abstract)
- Muindi Frankel J., Miller R. S, Jakubowski H., Scheinberg A., Young A. D, Dmitrovsky W. C, Warrell E. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 1992; 79(299)
- Delva Comic L., Balitrand M., Guidez N., Micl F., Sa J-M., Delmer Teillet A., Fenaux F., Castaigne P., Degos S., Chomienne L. C. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175–2181
- Estey Thall E., Mehta F. P, Rosenblum K., Brewer M., Jr., Simmons T., Cabanillas V., Kurzrock F., Lopez R., Berestein G. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 1996; 87: 3650–3654
- Estey Giles E., Kantarjian J. F, Cortes S., Freireich J., Lopez J. E, BeresteinKeating G. Molecular Remissions Induced by Liposomal-Encapsulated All-Trans Retinoic Acid in Newly Diagnosed Acute Promyelocytic Leukemia. Blood 1999; 94: 2230–223
- Thall P, Simon F. R, Estey E H. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 1995; 14: 296–303
- Tallman M, Andersen S., Schiffer W. J, Appelbaum A. C, Feusner R. F, Ogden H. J, Shepherd A., Willman L., Bloomfield C., Rowe D. CJM., Wiernik P H. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028
- Huang Ye M. Y-C, Chen S-R, Chai J-R, Lu J-X Zhoa, Gu L. L-J, Wang Z-Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
- Chen Z-X, Xue Y-Q, Zhangtao R. R-F, Xia X-M Li, Wang C., Zu W. W-Y, Yao X-Z, Ling B-J. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419
- Sun G-L, Zhou R-F Wu, Jiang W. G-S. Follow-up of 524 APL patients after CR induced by, ATRA. Leukemia 1994; 8: 1082
- Jurcic J, De Blasio G., Dumont T., Yao L. T-J, Scheinberg D A. Molecular remission induction with retinoic acid and anti CD-33 monoclonal antibody in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372–380